Mondor disease in a patient with psoriasis treated with an anti-interleukin 12/interleukin 23 investigational drug

Arch Dermatol. 2010 Sep;146(9):1049-50. doi: 10.1001/archdermatol.2010.232.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Biopsy, Needle
  • Drugs, Investigational / adverse effects*
  • Drugs, Investigational / therapeutic use
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Injections, Subcutaneous
  • Interleukin-12 / adverse effects*
  • Interleukin-12 / antagonists & inhibitors*
  • Interleukin-12 / therapeutic use
  • Interleukin-23 / adverse effects*
  • Interleukin-23 / antagonists & inhibitors*
  • Interleukin-23 / therapeutic use
  • Male
  • Middle Aged
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Risk Assessment
  • Severity of Illness Index
  • Subcutaneous Tissue / blood supply
  • Subcutaneous Tissue / pathology
  • Thoracic Wall
  • Thrombophlebitis / chemically induced*
  • Thrombophlebitis / pathology
  • Treatment Outcome

Substances

  • Drugs, Investigational
  • Interleukin-23
  • Interleukin-12